

## Special Issue

# Perspective of Metabolism: Potential Therapeutic Targets of Metabolic Diseases such as Obesity-Associated Diabetes, Atherosclerosis and Fatty Liver

### Message from the Guest Editor

Preclinical and clinical studies have shown that elevated levels of triglyceride-rich lipoproteins (TRL) and their remnant particles are associated with the development of type 2 diabetes (T2D), coronary atherosclerosis, and fatty liver. Under normal physiological conditions, triacylglycerol (TAG) is transported through the bloodstream in circulating TRL, including chylomicrons and very-low-density lipoproteins (VLDL). The imbalance between dyslipidemia (high levels of circulating TAGs and cholesterol) and ectopic lipid accumulation is critical in metabolic homeostasis. While reducing circulating lipids could help to prevent cardiovascular diseases such as atherosclerosis, excessive accumulation of lipids in tissues can lead to lipotoxicity and insulin resistance (IR). Therefore, the management of the serum lipoprotein profile could be an effective potential therapeutic target for the treatment of metabolic diseases. For this Special Issue, we invite articles related to a metabolic pathway based on lipid and glucose metabolism that reveal therapeutic targets against cardio-metabolic disease.


### Guest Editor

Dr. Abhishek Singh

Pharmacology, School of Medicine, Yale University, New Haven, CT, USA

### Deadline for manuscript submissions

closed (31 December 2022)



## Medicines

an Open Access Journal  
by MDPI

Indexed in PubMed




[mdpi.com/si/67280](https://mdpi.com/si/67280)

*Medicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[medicines@mdpi.com](mailto:medicines@mdpi.com)

[mdpi.com/journal/  
medicines](https://mdpi.com/journal/medicines)





# Medicines

---

an Open Access Journal  
by MDPI

---

Indexed in PubMed



[mdpi.com/journal/  
medicines](https://mdpi.com/journal/medicines)



## About the Journal

### Message from the Editor-in-Chief

*Medicines* (ISSN 2305-6320) is an international, peer-reviewed, and open-access journal aimed at disseminating cutting-edge research in the field of drug discovery and clinical application. It publishes original research papers, research communications, letters, and systematic reviews. The contents of the papers handled are manufacture of new drugs, exploration of drug-delivery systems, therapeutic effect, action mechanism, and their modulation by intrinsic and extrinsic factors. We look forward to handling your contributions in the very near future.

---

### Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1  
Keyakidai, Sakado, Saitama 350-0283, Japan

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 27.7 days after submission; acceptance to publication is undertaken in 7.2 days (median values for papers published in this journal in the second half of 2025).